A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
Whitehawk Therapeutics, Inc.
Eli Lilly and Company
Seagen Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
BioNTech SE
NiKang Therapeutics, Inc.
MacroGenics
SystImmune Inc.
Pheon Therapeutics
Eli Lilly and Company
Seagen Inc.
GlaxoSmithKline
Sairopa B.V.
Fate Therapeutics
NextCure, Inc.
NeoTX Therapeutics Ltd.
Radiopharm Theranostics, Ltd
West China Hospital
SystImmune Inc.
Incyte Corporation
NiKang Therapeutics, Inc.
Tempest Therapeutics
Pfizer
Exelixis
Lyell Immunopharma, Inc.
NextPoint Therapeutics, Inc.
Theratechnologies
Exelixis
Seagen Inc.
Seagen Inc.
Agenus Inc.
Checkpoint Therapeutics, Inc.
Compugen Ltd
Astellas Pharma Inc
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Vincerx Pharma, Inc.
Revolution Medicines, Inc.
Xencor, Inc.
Prelude Therapeutics
Institut Paoli-Calmettes
Corvus Pharmaceuticals, Inc.
Multitude Therapeutics Inc.
Fate Therapeutics
Xencor, Inc.